AGBL3: A Potential Drug Target for Neurodegenerative and Cardiovascular Disorders

Target Name: AGBL3

NCBI ID: G340351

AGBL3

AGBL3: A Potential Drug Target for Neurodegenerative and Cardiovascular Disorders

AGBL3 (Cytosolic Carboxypeptidase 3) is a protein that is expressed in various tissues throughout the body, including the brain, heart, lungs, and kidneys. It is a member of the carboxypeptidase family 3, which includes a variety of enzymes that are involved in the breakdown of carboxypeptides, which are a type of protein that consists of a carboxylic acid group and a peptidic chain.

One of the functions of AGBL3 is its role in the regulation of cellular signaling pathways. Specifically, it is involved in the breakdown of the neurotransmitter acetylcholine, which is involved in the regulation of memory and learning. In addition, AGBL3 is also involved in the breakdown of other signaling molecules, such as neurotransmitter GABA and endothelial factors.

In addition to its role in cellular signaling, AGBL3 is also a potential drug target. The high level of expression of AGBL3 in various tissues makes it an attractive target for small molecule inhibitors. Several studies have shown that inhibitors of AGBL3 have the potential to treat a variety of diseases, including neurological and cardiovascular disorders.

One of the potential benefits of targeting AGBL3 is its potential to treat neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to contribute to the underlying causes of these diseases. In addition, AGBL3 has been shown to be involved in the regulation of neurotransmitter synthesis and release, which may be involved in the pathophysiology of these conditions.

Another potential application of AGBL3 is its potential to treat cardiovascular disease. The breakdown of carboxypeptides by AGBL3 has been shown to be involved in the regulation of smooth muscle contractions and vasorelaxation, which may be involved in the pathophysiology of cardiovascular disease. In addition, AGBL3 has been shown to be involved in the regulation of fibrosis, which is a process that contributes to the development of cardiovascular tissue.

In addition to its potential therapeutic applications, AGBL3 is also a valuable biomarker for a variety of cardiovascular and neurological conditions. The breakdown of carboxypeptides by AGBL3 may be involved in the development of various cardiovascular and neurological disorders, including myocardial infarction, hypertension, and neurodegenerative diseases. In addition, AGBL3 has been shown to be involved in the regulation of neurotransmitter synthesis and release, which may be involved in the pathophysiology of these conditions.

Overall, AGBL3 is a protein that is involved in a variety of cellular and physiological processes throughout the body. Its role in the regulation of cellular signaling pathways and its potential as a drug target make it an attractive target for small molecule inhibitors. Further research is needed to fully understand the functions of AGBL3 and its potential as a therapeutic agent.

Protein Name: AGBL Carboxypeptidase 3

Functions: Metallocarboxypeptidase that mediates deglutamylation of tubulin and non-tubulin target proteins. Catalyzes the removal of polyglutamate side chains present on the gamma-carboxyl group of glutamate residues within the C-terminal tail of tubulin protein. Specifically cleaves tubulin long-side-chains, while it is not able to remove the branching point glutamate. Also catalyzes the removal of polyglutamate residues from the carboxy-terminus of non-tubulin proteins such as MYLK. May catalyze the hydrolysis of aspartate from the carboxy-terminus of target proteins. Does not show detyrosinase or deglycylase activities from the carboxy-terminus of target proteins

The "AGBL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AGBL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets